Superba krill oil tapped for joint, eye care
Valensa International on Tuesday announced it reached an exclusive agreement with Aker BioMarine to use the Norwegian company’s Superba krill oil in its range of dietary supplements.
Valensa will use omega-3 phospholipids from Aker BioMarine’s Superba krill oil, in conjunction with several of its own proprietary ingredients, to extend its line of patented and patent-pending formulations.
“We’re excited to be working with Aker BioMarine because of their product quality, their vision, their energy and their commitment to driving the use of Superba™ krill oil to improve human health,” said Rudi Moerck, Valensa president and CEO. “They have an excellent understanding of the market potential for this ingredient, world-class supply ability and are excited about Valensa’s plans to bring Superba™ krill oil to market in condition-specific formulas.”
The company also said it believes the potential for Superba krill-based formulas is substantial.
“Joint and eye health are major concerns for many people including the aging baby-boomer population who also want small dosage forms that are easy to use on a regular basis,” said Moerck. “The increased potency of formulas containing Superba krill allows formulators and marketers to substantially reduce the size of their softgels and dramatically reduce the overall ‘pill burden’ on people.”
On 6 October, Valensa announced that it reached a similar agreement involving krill oil with Neptune Technologies & Bioresources. Valensa said it terminated the agreement on 9 November due to irreconcilable differences between the two companies over the ability of Neptune to deliver the product it had promised and differing interpretations of agreement language. Discussions with Aker BioMarine began after the termination of the agreement with Neptune, according to Valensa.
Last month, Neptune filed a patent infringement lawsuit against Aker BioMarine, accusing the company of breaching a patent for a method of extracting lipid fractions from krill.